[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"spasmodic-dysphonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:spasmodic-dysphonia":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,74,96,110,128],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100596111","phase-1-extended-release-sodium-oxybate-lumryz-in-spasmodic-dysphonia-and-voice-tremor-100596111",false,"NCT07041203","Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor","Central Mechanisms and Treatment Response of Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor","Inclusion Criteria:\n\n1. Provision of signed and dated informed consent form\n2. Stated willingness to comply with all study procedures and lifestyle considerations (see Lifestyle Considerations below) and availability for the duration of the study\n3. Males and females\n4. Age 21-80 years\n5. Documented diagnosis of alcohol-responsive laryngeal dystonia\n6. Documented positive response to immediate-release sodium oxybate (Xyrem) in prior studies\n7. Willingness to adhere to the study intervention regimen\n\nExclusion Criteria:\n\n1. The incapability of giving informed consent\n2. Pregnancy or breastfeeding until a time when they are no longer pregnant or breastfeeding\n3. Grade 2 or higher hepatic or renal dysfunction according to the NCI criteria\n4. Moderate to severe congestive heart failure\n5. Cognitive impairment (MoCA \\\u003C 26)\n6. Past or present suicidal ideations (according to C-SSRS)\n7. Alcoholism or high risk for alcohol use disorder according to the NIAAA definition and DSM-5 criteria\n8. Asymptomatic presentation due to botulinum toxin treatment until the time they are fully symptomatic and are at least 3 months after the last injection\n9. Increased daytime sleepiness (Epworth Sleepiness Scale (ESS\\>10))\n10. Past or present history of any neurological disorders (except for LD and co-occurring voice tremor), such as stroke, movement disorders, brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug dependence.\n11. Past or present history of any psychiatric problems, such as schizophrenia, major and\u002For bipolar depression, or obsessive-compulsive disorder\n12. Current use of medication(s) affecting the central nervous system\n13. Past or present history of brain and\u002For laryngeal surgery\n14. Presence of certain tattoos, ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve, etc.) that are not MRI comparable and\u002For cannot be removed for the purpose of MRI study participation","ALL","21 Years","80 Years",{"count":20,"type":21},8,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Using a comprehensive approach of clinico-behavioral testing and neuroimaging, the researchers will examine the clinical effects of the extended-release formulation of sodium oxybate on voice symptoms in spasmodic dysphonia in an open-label, proof-of-concept, dose-finding study.",[27,28,29],"Spasmodic Dysphonia","Laryngeal Dystonia","Voice Tremor","NOT_YET_RECRUITING","2026-04-25",{"date":33,"type":34},"2026-04-28","ACTUAL",{"date":36,"type":21},"2026-10-01",{"date":38,"type":21},"2027-09-30",{"name":40,"class":41},"Kristina Simonyan","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":42},"100289070","brain-networks-in-dystonia-100289070","NCT03042962","Brain Networks in Dystonia","Inclusion Criteria:\n\n* Patients will have clinically documented focal dystonia\n* Unaffected relatives of patients with focal dystonia\n* Healthy controls will be healthy volunteers with a negative history of neurological, laryngeal or psychiatric problems\n* Age from 21 to 80 years.\n* Native English speakers.\n* Right-handedness (based on Edinburgh Handedness Inventory).\n\nExclusion Criteria:\n\n* Subjects who are incapable of giving an informed consent.\n* Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed, which must be negative for participation in the imaging studies.\n* Subjects with past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than dystonia in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug depend-ence; (b) psychiatric problems, such as schizophrenia, major and\u002For bipolar depression, obsessive-compulsive disorder; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis.\n* Patients who are not symptomatic due to treatment with botulinum toxin injections into the laryngeal muscles. The duration of positive effects of botulinum toxin vary from patient to patient but lasts on average for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic prior to entering the study.\n* Patients with other forms of dystonia.\n* Patients who have dystonia symptoms at rest in order to avoid the potential confound of dystonic spasms occurring during the scanning.\n* To avoid the possibility of confounding effects of drugs acting upon the central nervous system, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial intake screening. Those patients who receive medication(s) affecting the central nervous system will be excluded from the study.\n* The patients will be asked whether they have undergone any head, neck, or hand surgeries, which resulted in changes in regional anatomy or innervation. Because brain, hand and laryngeal surgery may potentially lead to the brain structure and function re-organization, all patients with history of brain, hand and\u002For laryngeal surgery will be excluded from the study.\n* Subjects who have tattoos, ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve, etc.) that cannot be removed for the purpose of study participation.",true,{"count":51,"type":21},141,"OBSERVATIONAL","To date, there is only limited knowledge about the distinct neural abnormalities that lead to the development of different forms of focal dystonia. The goal of this study is to dissect the pathophysiological mechanisms underlying this clinical phenomenon using multi-level brain network analysis in patients with focal dystonia.",[27,55,56,57,58,59],"Singer's Dystonia","Writer's Cramp","Musician's Focal Hand Dystonia","Craniofacial Dystonia","Blepharospasm Oromandibular Dystonia",[61,62,63],"dystonia","imaging","genetics","RECRUITING","2025-12-01",{"date":67,"type":34},"2025-12-08",{"date":69,"type":34},"2015-08-01",{"date":71,"type":21},"2027-12-31",{"name":73,"class":41},"Massachusetts Eye and Ear Infirmary",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":49,"sex":16,"minAge":80,"maxAge":18,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":42},"100455915","early-phase-1-understanding-disorder-specific-neural-pathophysiology-in-laryngeal-dystonia-and-voice-tremor-100455915","NCT05216770","Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic background;\n2. Age 18-80 years;\n3. Native English speakers;\n4. Right-handed;\n5. Normal cognitive status;\n6. Patients will have laryngeal dystonia or voice tremor;\n7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent;\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;\n4. Patients with any other form of dystonia;\n5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;\n6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;\n7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;\n8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;\n9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.","18 Years",{"count":82,"type":21},165,[84],"EARLY_PHASE1","The researchers will examine functional neural correlates that differentiate between laryngeal dystonia and voice tremor and contribute to disorder-specific pathophysiology using a cross-disciplinary approach of multimodal brain imaging.",[28,27,87],"Tremor","2025-11-24",{"date":90,"type":34},"2025-12-02",{"date":92,"type":34},"2022-03-24",{"date":94,"type":21},"2027-08-31",{"name":73,"class":41},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":49,"sex":16,"minAge":80,"maxAge":18,"enrollmentInfo":102,"targetDuration":4,"studyType":52,"phases":4,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":105,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":109,"locationsCount":42},"100450792","characterization-of-clinical-phenotypes-of-laryngeal-dystonia-and-voice-tremor-100450792","NCT05150106","Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic backgrounds;\n2. Age 18-80 years;\n3. Native English speakers;\n4. Right-handed;\n5. Normal cognitive status;\n6. Patients will have laryngeal dystonia or voice tremor;\n7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent;\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;\n4. Patients with any other form of dystonia;\n5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;\n6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;\n7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;\n8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;\n9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.",{"count":82,"type":21},"The researchers will systematically evaluate current and novel clinical voice assessment tools and measures to elucidate distinct clinical phenotypes of those with laryngeal dystonia and voice tremor.",[28,27,87],{"date":90,"type":34},{"date":107,"type":34},"2022-11-07",{"date":94,"type":21},{"name":73,"class":41},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":18,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":123,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":127,"locationsCount":42},"100450791","deep-brain-stimulation-in-laryngeal-dystonia-and-voice-tremor-100450791","NCT05150093","Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor","Inclusion\n\n1. Clinical indications to proceed with DBS implantation, as determined by the clinical multidisciplinary movement disorders board, including: a) definitive diagnosis of essential tremor or dystonia, b) medically refractory disease, c) adequate performance on neuropsychological evaluation as determined by a licensed clinical neuropsychologist.\n2. The ability to comply with test directions, complete pre-operative task training, and provide informed consent.\n3. Age 18-80 years.\n\nExclusion\n\n1\\. Inability to understand or perform the task outlined in the protocol during a pre-surgery training session. 2. Significant hearing loss.\n\n3\\. Cortical venous anatomy that could potentially obstruct ECoG electrode placement, as determined by the surgeon, visualized on pre-op MRI or during surgery.",{"count":117,"type":21},120,[119],"NA","The goals of this project are 1) to determine the incidence of neurological voice disorders in patients with dystonia and essential tremor undergoing deep brain stimulation (DBS), 2) investigate the neuroimaging and intracranial neurophysiology correlates of voice dysfunction in these subjects, and subsequently 3) determine the effects of DBS on voice function.",[28,27,87,122],"Dystonia",{"date":90,"type":34},{"date":125,"type":34},"2022-06-21",{"date":94,"type":21},{"name":73,"class":41},{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":149,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":42},"100522123","assessment-of-laryngopharyngeal-sensation-cancer-survivor-cohort-100522123","NCT06078527","Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort","Assessment of Laryngopharyngeal Sensation in Patients With Laryngopharyngeal Disorders","Inclusion Criteria:\n\n1. Age \\\u003C=18 years.\n2. Individuals without a laryngopharyngeal disorder (health controls) or with a laryngopharyngeal disorder. Laryngopharyngeal disorder includes but is not limited to: presbylarynx, aspiration; spasmodic dysphonia; globus pharynges; vocal fold paralysis; iatrogenic injury to the larynx; muscle tension dysphonia; neurogenic dysphagia; laryngeal sensory neuropathy; and laryngopharyngeal disorders resulting from prior radiation therapy in individuals with a history of head and neck cancer who have completed radiation therapy as primary or adjuvant cancer treatment\n3. Ability and willingness to comply with study procedures.\n4. Ability to understand a written informed consent document, and the willingness to sign it.\n\nExclusion Criteria:\n\n1. Non-English speaking.\n2. Laryngopharyngeal structures are not accessible on exam.\n3. Known contraindication to any study-related procedure, or history of being unable to tolerate laryngoscopy.\n4. Vocal fold immobility or severe hypomobility on adduction.\n5. For head and neck cancer survivors only: Currently undergoing radiation therapy for head and neck cancer (i.e., primary\u002Fadjuvant radiation therapy treatment plan is not yet completed).","85 Years",{"count":137,"type":21},40,[119],"A previous study completed in 2022 (NCT05158179) was conducted using cohorts of healthy controls, and adults with general laryngopharyngeal disorders. This study will expand on the previous research to include a separate cohort of adults being seen in clinic for an existing laryngopharyngeal disorder resulting from previous radiation or other cancer treatments.",[141,142,27,143,144,145,146,147,148],"Presbylarynx","Aspiration","Globus Pharyngeus","Larynx Paralysis","Laryngeal Disease","Vocal Cord Paralysis","Iatrogenic Injury","Sensory Neuropathy",[150,151,152],"Cancer survivors","Previous cancer treatment","Laryngopharyngeal disorders","2025-07-21",{"date":155,"type":34},"2025-07-23",{"date":157,"type":21},"2025-10-01",{"date":159,"type":21},"2028-01-31",{"name":161,"class":41},"University of California, San Francisco"]